Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children

Journal of Pediatric Hematology/Oncology

Volumn 21, Issue 4, 1999, Pages 268-273

  Schmiegelow, M ^a   Hertz, H ^a   Schmiegelow, K ^a   Holm, K ^a   Muller J ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Acute lymphocytic leukemia; Child; Insulin like growth factor binding proteins; Insulin like growth factor I; Mercaptopurine; Methotrexate

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARAGINASE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY GROWTH; BODY MASS; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HORMONE RELEASE; HUMAN; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; RADIOIMMUNOASSAY;

EID: 0033505036     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199907000-00006     Document Type: Article

References (33)

1. Moell C, Garwicz S, Marky I, et al. Growth in children treated for acute lymphoblastic leukemia with and without prophylactic cranial irradiation. Acta Paediatr Scand 1988;77:688-92.
2. Livesey EA, Hindmarsh PC, Brook CG, et al. Endocrine disorders following treatment of childhood brain tumours. Br J Cancer 1990; 61:622-5.
3. Christie D, Leiper AD, Chessells JM, et al. Intellectual performance after presymptomatic cranial radiotherapy for leukaemia: effects of age and sex. Arch Dis Child 1995;73:136-40.
4. Haupt R, Fears TR, Robison LL, et al. Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia. JAMA 1994;272:1427-32.
5. Ilveskoski I, Pihko H, Wiklund T, et al. Neuropsychologic late effects in children with malignant brain tumors treated with surgery, radiotherapy, and "8 in 1" chemotherapy. Neuropediatrics 1996;27:124-9.
6. Schmiegelow K, Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 1990;61:767-72.
7. Schmiegelow K, Schroeder H, Schmiegelow M. Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters? Cancer Chemother Pharmacol 1994; 34:209-15.
8. Schmiegelow K, Schroeder H, Gustafsson G, et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 1995;13:345-51.
9. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 1994;343: 1188-90.
10. Holm K, Nysom K, Hertz H, et al. Normal final height after treatment for acute lymphoblastic leukemia without irradiation. Acta Paediatr 1994;83:1287-90.
11. Katz JA, Pollock BH, Jacaruso D, et al. Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia. J Pediatr 1993;123:546-52.
12. Morris MJ. In vitro effects of anti-leukemic drugs on cartilage metabolism and their effects on somatomedin production by the liver. Doctoral thesis. Manchester University, 1981, Manchester, UK.
13. Price DA, Morris MJ, Roswell KV, et al. The effects of antileukemic drugs on somatomedin production and cartilage responsiveness to somatomedin in vitro. Pediatr Res 1981;15:1553.
14. Wilson KS, Gray CE, Cameron EHD, et al. Hypothalamic/ pituitary/adrenal function in patients treated with intermittent high-dose prednisolone and cytotoxic chemotherapy. Lancet 1976;1: 610-12.
15. Blum WF, Ranke MB. Use of insulin-like growth factor binding protein-3 for the evaluation of growth disorders. Horm Res 1990;33(Suppl):31-7.
16. Baxter RC, Martin JL. Regulation and actions of insulin-like growth factor binding protein-3. Adv Exp Med Biol 1991;293:125-35.
17. Blum WF, Albertsson Wikland K, Rosberg S, et al. Serum levels of insulin-like growth factor I (IGF-1) and IGF-binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993;76:1610-16.
18. Counts DR, Gwirtsman H, Carlsson LMS, et al. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs). and the IGF-binding. J Clin Endocrinol Metab 1992;75:762-7.
19. Isley WL, Underwood LE, Clemmons DR. Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest 1983;71:175-82.
20. Marky I, Mellander L, Lannering B, et al. A longitudinal study of growth and growth hormone secretion in children during treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 1991;19: 258-64.
21. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II. IG-FBP-1. IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534-42.
22. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-52.
23. Kamen BA, Takach PL, Vatev R, et al. A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 1976;70:54-63.
24. Bruunshuus I, Schmiegelow K. Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-performance liquid chromatography. Scand J Clin Lab Invest 1989;49:779-84.
25. Andersen E. Height and weight in Danish children. Ugeskr Laeger 1982;144:1760-5.
26. Norusis MJ. SPSS statistical software 5.0. Chicago, IL: SPSS, 1992.
27. Siegel S, Castellan NJ. Nonparametric statistics for the behavioral sciences. Singapore: McGraw-Hill, 1988.
28. Hasegawa Y, Hasegawa T, Aso T, et al. Comparison between insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IG-FBP-3) measurement in the diagnosis of growth hormone deficiency. Endocr J 1993;40:185-90.
29. Sela M, Gedalia I, Shah L, et al. Enamel rehardening with cheese in irradiated patients. Am J Dent 1994;7:134-6.
30. Barrett AJ. Bone marrow transplantation for acute lymphoblastic leukaemia. Baillieres Clin Haematol 1994;7:377-401.
31. Gwavava NJ, Pinkerton CR, Glasgow JF, et al. Small bowel enterocyte abnormalities caused by methotrexate treatment in acute lymphoblastic leukaemia of childhood. J Clin Pathol 1981;34: 790-5.
32. McIntosh S, Davidson DL, O'Brien RT, et al. Methotrexate hepatoxicity in children with leukemia. J Pediatr 1977;90:1019-21.
33. Mohnike KL, Kluba U, Mittler U, et al. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 1996;155:81-6.